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Abstract
Background: The prevention and treatment of cognitive decline in the elderly population is reaching an
increasing significance as people are living longer than they have in the past due to better healthcare services.
Dementia is a major contributor to morbidity and mortality in the aging population, and society would greatly
benefit from strategies to delay or decrease the progression. It has been suggested that certain medications,
dietary measures, mental activity, and exercise may decrease the risk of cognitive impairment in the elderly
population. There has been mixed evidence that people who use a specific cholesterol lowering medication,
the HMG-CoA reductase class, better known as statins, are less likely to develop dementia. However, direct
evidence of statin effects of neuropathologic markers of Alzheimer’s disease is lacking. This paper will review
recent research on the usage of statins in the treatment of dementia and its efficacy and validity.
Methods: A systematic review of the past six years of published literature was conducted using the search
engines MEDLINE, CINAHL, and PubMed using keywords dementia, Alzheimer’s, cognitive decline, and
statins. Relevant references were retrieved and reviewed. Original research and cohort studies that included
statin usage and cognitive decline were analyzed. Meta-analyses were excluded. Only studies published within
the past six years were analyzed. The population included older adults greater than 60 years old who did not
have baseline dementia at the time the study was initiated, and who used statin therapy for at least four
months, monitored over the course of at least five years. Articles of original research that examined the effects
of statin medications on cognitive function were selected. Seven studies were selected that met the above
criteria, and were analyzed for quality and significant results.
Results: Results from studies varied as to whether statins had any protective effects in the decline of dementia.
Some studies made conclusions based on patient’s function on cognitive tests alone, while other looks into
more advanced tests such as cranial MRI scans or even brain biopsies. Of the seven studies reviewed, three
concluded a decrease in cognitive decline while taking a statin medication, however four did not. One exam
looked into cognitive decline as well as brain biopsies and found that although there was no significant change
in cognitive outcome, there were some benefits on brain autopsy of statin users. However, another study
where brain biopsies were performed did not find any significant improvement due to statin medications.
MRI analysis did not yield any significant benefit from statin drugs.
Conclusion: Based on the above results, there are no significant consistent indications to use statins in the
prevention of dementia. Statins may play a role in limiting cognitive decline, however more detailed analysis
needs to be performed in order to better understand the role that statins play.
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Abstract   
 
 
Background:  The prevention and treatment of cognitive decline in the elderly 
population is reaching an increasing significance as people are living longer than they 
have in the past due to better healthcare services.  Dementia is a major contributor to 
morbidity and mortality in the aging population, and society would greatly benefit from 
strategies to delay or decrease the progression.  It has been suggested that certain 
medications, dietary measures, mental activity, and exercise may decrease the risk of 
cognitive impairment in the elderly population. There has been mixed evidence that 
people who use a specific cholesterol lowering medication, the HMG-CoA reductase 
class, better known as statins, are less likely to develop dementia.  However, direct 
evidence of statin effects of neuropathologic markers of Alzheimer’s disease is lacking1. 
This paper will review recent research on the usage of statins in the treatment of dementia 
and its efficacy and validity.  
Methods:  A systematic review of the past six years of published literature was 
conducted using the search engines MEDLINE, CINAHL, and PubMed using keywords 
dementia, Alzheimer’s, cognitive decline, and statins. Relevant references were retrieved 
and reviewed.   Original research and cohort studies that included statin usage and 
cognitive decline were analyzed. Meta-analyses were excluded.  Only studies published 
within the past six years were analyzed. The population included older adults greater than 
60 years old who did not have baseline dementia at the time the study was initiated, and 
who used statin therapy for at least four months, monitored over the course of at least five 
years.   
Articles of original research that examined the effects of statin medications on cognitive 
function were selected. Seven studies were selected that met the above criteria, and were 
analyzed for quality and significant results.  
Results:  Results from studies varied as to whether statins had any protective effects in 
the decline of dementia.  Some studies made conclusions based on patient’s function on 
cognitive tests alone, while other looks into more advanced tests such as cranial MRI 
scans or even brain biopsies.  Of the seven studies reviewed, three concluded a decrease 
in cognitive decline while taking a statin medication, however four did not. One exam 
looked into cognitive decline as well as brain biopsies and found that although there was 
no significant change in cognitive outcome, there were some benefits on brain autopsy of 
statin users.  However, another study where brain biopsies were performed did not find 
any significant improvement due to statin medications.  MRI analysis did not yield any 
significant benefit from statin drugs. 
Conclusion:  Based on the above results, there are no significant consistent indications to 
use statins in the prevention of dementia.  Statins may play a role in limiting cognitive 
decline, however more detailed analysis needs to be performed in order to better 
understand the role that statins play.  
Keywords:  Statins, dementia, Alzheimer’s disease, cognitive decline 
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The Effects of HMG-CoA Reductase Inhibitors in the Prevention of Dementia in the 
Elderly Population  
 
BACKGROUND 
Dementia is a condition characterized by memory impairment and at least one 
other cognitive domain (apraxia, agnosia, aphasia, executive function). It is estimated to 
affect more than four million Americans and up to 3.1 million caregivers of those with 
Alzheimer’s Disease.1,2   To diagnose, there must have been a decline from a previous 
level of function and it must have been severe enough to interfere with independence and 
daily function. The major types of dementia include: Alzheimer’s disease, vascular 
dementia, Lewy Body Dementia, Parkinson disease with dementia, Frontotemporal 
dementia, and reversible dementias.  Alzheimer’s dementia accounts for 60-80% of 
dementias, with vascular dementia the next most common, accounting for 10-20% of 
dementia.3  
Alzheimer’s disease (AD) is a neurodegenerative disorder that primarily affects 
older adults over age 60, more commonly women, with the prevalence increasing with 
age. The cause and pathogenesis is uncertain. The cost of caring for one patient with AD 
is $47,000 per year.2 Many treatments are available that can alter the course of the 
disease or lessen the symptoms, but there is no cure, and the disease inevitably advances 
in all patients.3 
There are many clinical features that accompany AD.  Memory impairment is 
often the earliest manifestation.  Declarative memory for facts and events is profoundly 
affected, while procedural and motor learning are usually spared until quite late in the 
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disease. Memory for recent events is controlled by the hippocampus, entorhinal cortex, 
and other structures in the mesial temporal lobe are usually impaired early in AD.  
Memories that are formed over long periods of time (years) are usually spared early on, 
since they can be remembered without hippocampal function.   Language problems also 
occur with the earliest manifestations including word-finding difficulties, circumlocution, 
and reduced vocabulary in spontaneous speech with anomia.  Later language findings 
include agrammatism, impoverished speech content, impaired comprehension, and 
paraphasic errors.   Loss of visuospatial skills can also be an early sign, including 
misplacement of items and difficulty finding their way in unfamiliar terrain, progressing 
to familiar terrain.  Later features include the inability to recognize objects (visual 
agnosia) or faces (prosopagnosia).3  Alzheimer’s disease patients may also develop 
decreased awareness of their deficits, which has been linked to frontal lobe pathology.  
They underestimate their deficits or offer explanations for them.  Difficulty performing 
learned motor tasks (apraxis) occur later in the disease process after memory and 
language deficits are apparent.   Executive function, in which patients may present with 
an alteration of personality, poor judgment and planning, and the inability to complete 
tasks, can be affected.  Later in the disease, neuropsychiatric symptoms, including 
apathy, social disengagement, and disinhibition, become more common. These can 
progress to more severe behavioral disturbances including wandering, aggression, 
agitation, and even psychosis.3 
Hippocampal volume loss of MRI is highly correlated with AD, but does not 
diagnose.  Diagnosis can only be done by autopsy; the brains of those with AD are 
characterized by extracellular deposition of amyloid-beta proteins, intracellular 
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neurofibrillary tangles, and loss of neurons. The abnormal processing of amyloid-beta 
protein is likely to be the cause of AD.  A group of amyloid precursor proteins can be 
cleaved by certain secretases. When the amyloid proteins are cleaved on the amino end 
by a beta-secretase and on the carboxy end by a gamma-secretase, an Abeta42 protein is 
released.  Abeta42 then accumulates in diffuse plaques, which are thought to change into 
the thick neuritic plaques. Increased amounts of Abeta42 and Abeta oligomers are found 
in the cerebrospinal fluid and brain tissue of patients with early dementia and show a 
relationship with cognitive decline, supporting the hypothesis that small Abeta oligomers 
rather than amyloid plaques are the mediators of neurotoxicity in Alzheimer’s disease.1,4   
When the dense neuritic plaque forms, excitotoxicity, inflammation, and even apoptosis 
cause damage. Neurofibrillary tangles (NFTs) are a hyperphosphorylated type of 
microtubule-like protein Tau.1  
Alzheimer’s disease progression is typically measured with the Mini-Mental Status 
Examination (MMSE) and the Clinical Dementia Rating Scale.   A number of studies 
have found that patients decline on average 3 to 3.5 points on the MMSE each year 
without any specific intervention.3  
• MMSE score 20-26: Mild functional dependence (difficulty managing finances) 
• MMSE score 10-20: Moderate functional impairment (inability to drive, difficulty 
with hygiene and shopping, remote memory impairment) 
• MMSE score <10: state of total dependence and need for constant supervision.  Motor 
impairments such as gait and balance are affected, as well as incontinence, 
myoclonus, and total debility.3  
 10 
After diagnosis of AD, mean survival ranges from three to eight years.  Patients 
often succumb to end stage complication such as dehydration, malnutrition, and infection.  
A definitive diagnosis of AD requires a histopathologic examination which is rarely done 
while the patient is alive.3  
There are many other types of dementia.  Vascular dementia is caused by either 
ischemic or hemorrhagic strokes, commonly due to small vessel cerebrovascular disease.  
It is usually suggested by onset of cognitive deficits after a stroke, abrupt onset of 
symptoms, findings on neurological exam consistent with a prior stroke, and infarcts 
shown on cerebral imaging.  Frontotemporal dementia is characterized by atrophy of the 
frontal or temporal lobe, often manifested by changes in personality, behavior, and 
executive functioning early in the disease. Typical manifestations, which are prominent 
early in the course of the disease, include abnormal social behavior, unusual eating 
patterns, ritualized behaviors, and difficulty finding words, while cognitive disturbance is 
usually minimal at onset. Lewy Body Dementia is the second most common type of 
dementia after AD.3 Features include early appearance of visual hallucinations, 
spontaneous motor features of Parkinson’s, cognitive changes, dysautonomia, sleep 
disorders, and neuroleptic sensitivity.3  
Risk factors for dementia include smoking, hypertension, Diabetes Mellitus type 
2, high homocysteine levels, insulin resistance, hypercholesterolemia, and obesity. Being 
positive for the allele Apolipoprotein E epsilon 4 also is a risk factor for Alzheimer’s, 
however this allele has a low prevalence. ApoE plays a role in lipid metabolism and is the 
main transport protein for cholesterol into the brain.5,6 Factors that have been shown to 
decrease the risk of dementia include: higher education, physical exercise, mental 
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exercise, diets high in fish, fruits, and vegetables, antioxidants (Vitamin E), and B 
Vitamins (Folate, B6, and B12).7 Contributors to chronic dementia include medications 
(such as antihistamines), alcohol, depression, central nervous system neoplasms, 
hematomas, or meningitis, and metabolic disorders and deficiencies.2  
Alzheimer’s disease (AD) is the most common type of dementia accounting for 
69.9%, while vascular dementia (VaD) is the next most common at 17.4%.  The other 
12.7% included Parkinson’s dementia, Lewy body dementia, normal-pressure 
hydrocephalus, frontal lobe dementia, alcoholic dementia, traumatic brain injury.3  
Alzheimer’s disease is a degenerative disorder that begins insidiously and 
progresses gradually over time.  Detection of early stage dementia, or Mild Cognitive 
Impairment (MCI), can be the imperative time to begin treatment to slow the progression 
of the disease.  The rate of progression to clinically diagnosable Alzheimer’s disease 
from MCI is 10-15% per year, relative to 1-2% in the normal elderly population.3,8,9  
Since dementia is a progressive disease, benefit can be measure not only with 
improvement on a test, such as the MMSE, but also by stabilization or a decrease in the 
rate of decline. So even though there may still be a decrease in cognition, the rate of 
decline may indicate a benefit when compared to a placebo group.  An expected decline 
in the placebo group is an important factor in order to compare the change in the subject’s 
mentation.  
Statins are a commonly used cholesterol lowering medication that work by 
reducing the cholesterol production by the liver. They block the enzyme, hydroxyl-
methylglutaryl-coenzyme A reductase (HMG-CoA reductase) that is responsible for 
making cholesterol.10 The mechanism by which statins may affect the pathogenesis of 
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dementia is uncertain. Cholesterol is essential for normal function of the brain, so this 
was originally thought to be an underlying mechanism, however, the brain cholesterol is 
synthesized in situ, and the BBB prevents exchange of cholesterol with the periphery.10  
It was originally hypothesized that only lipophilic statins would play a role in this, since 
they are able to cross the BBB, however this theory has not been proven.5   
Purpose of the Study 
The purpose of this study is to systematically review recent research regarding the 
usage of statins in the prevention of cognitive decline.  The ideal research would control 
for potential confounders, and have a large enough number of participants to permit 
clinically significant results. 
Clinical Question 
Alzheimer’s disease and other forms of dementia have become so pervasive in our 
communities affecting more and more people both directly and indirectly and heavily 
impacting the healthcare system. It is imperative that the causes and treatments for such a 
widespread problem be addressed.  There are many well established preventative 
measures, but the use of statin drugs in still one that is under investigation. There have 
not been any consistent results that statins are indeed a good prevention option for 
Alzheimer’s disease.  
METHODS 
Search Strategy 
A systematic review of the past six years of published literature was conducted 
using the search engines MEDLINE, CINAHL, and PubMed using keywords dementia, 
Alzheimer’s, cognitive decline, and statins. Relevant references were retrieved and 
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reviewed.   Original research and cohort studies that looked at statin usage and cognitive 
decline were analyzed. Meta-analyses were excluded.  Only studies published within the 
past six years were analyzed.  
Inclusions/Exclusions 
The population of interest included adults greater than 60 years old who did not 
have baseline dementia at the time the study was initiated.  The search was limited to 
English language publications. 
Inclusion criteria included human studies, subjects greater than 60 years old at the 
time the study began, mental examination of patients at least once per year, and statin 
usage for greater than four months. Included studies contained greater than 100 
participants, and followed patients for more than five years.  Age, sex, smoking status, 
presence of diabetes of high blood pressure, education, and the presence of the ApoE 
allele were adjusted for in each study. 
Exclusion criteria included studies in which patients were not physically 
examined at least once per year, patients who had baseline dementia at the start of the 
study, studies which tried statin therapy for less than 4 months, and studies which 
included other drugs than statins for the treatment of dementia. Animal studies were also 
excluded.  
RESULTS 
Articles of original research that examined the effects of statin medications on 
cognitive function were selected. Seven studies were selected that met the above criteria, 
and were analyzed for quality and significant results.  Table 1 shows a summary matrix 
of selected studies.  These various studies demonstrated variations on whether statins had 
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any protective effects against the decline of dementia.  Some studies made conclusions 
based on patient’s function on cognitive tests alone, while other looked into more 
advanced tests such as cranial MRI scans or even brain biopsies.  Of the seven studies 
reviewed, three concluded there was a decrease in cognitive decline while taking a statin 
medication, however four saw no effect, positive or negative. One study looked into 
cognitive decline as well as brain biopsies and found that although there was no 
significant change in cognitive outcome, there were some benefits on brain autopsy of 
statin users.  However, another study that performed brain biopsies did not find any 
significant improvement while on statin medications.  MRI analysis did not reveal any 
significant benefit from statin drugs either.  
The Rotterdam Study,5 published in 2008, is a prospective, population-based 
cohort study of age related diseases.  Between 1990 and 1993, 6992 participants were 
entered in the study, all free of dementia.  Patients were monitored in 1993-1994, 1997-
1999, and 2000-2004 using MMSE and GMS screening and clinical work up for 
dementia. Pharmacy records of all patients were tracked.  Only patients who proved they 
had taken medications for at least six months were included in the study.  Cholesterol 
medications were monitored, particularly statins, and grouped into lipophilic or 
hydrophilic categories.  Lipophilic medications, including simvastatin, pravastain, 
flucastatin, atorvastatin, rosuvastatin) are known to pass the BBB more efficiently.  
Hydrophilic statins include pravastatin, fluvastatin, and rosuvastatin which do not cross 
the BBB.5  
The diagnosis of dementia was based on a 3 step protocol.  Screening procedures 
included the Mini-Mental Status Examination (MMSE) and Geriatric Mental State 
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Schedule (GMS).  Positive results included MMSE <26 or GMS >0. These patients with 
positive results underwent Cambridge examinations for mental disorders, and those who 
were suspected of having dementia underwent a more extensive neurological testing.   
Imaging data was used as needed. The diagnosis of dementia was made according to 
criteria from the DSM-III-R, and Alzheimer’s disease and vascular dementia criteria 
consisting of a panel of a neurologist, neurophysiologist, and a research physician, who 
were all blinded to the drug exposure.  Characteristics that were looked at included age, 
with the average being 69.4 years, sex (60% female), smoking, DM, Blood Pressure, 
cardiovascular disease, stroke, total cholesterol, BMI, education level, and presence of 
the ApoE4 allele (+25.6%).5 
A total of 6992 patients who were all free of dementia who had taken medications 
for at least six months were examined at baseline.  Patients followed up to 15.3 years, 
with the average being 9.2 years.  Of these, 739 developed dementia (582 were 
Alzheimer’s, 81 were vascular dementia, 76 other types of dementia).  The total number 
of prescriptions filled was 30 241.  Simvastatin was the most frequently used statin (the 
most lipophilic statin) followed by pravastatin (the most hydrophilic statin).  It was found 
that the use of statins was associated with a lower risk of AD than those who had never 
used statin medications. However, there was no strong evidence for lipophilic statins 
providing stronger protection than a hydrophilic statin (adjusted OR: 0.61, 95% CI 0.36 
to 1.03 for lipophilic and 0.38; 95% 0.15 to 0.99 for hydrophilic). There was no dose 
dependent relationship detected; doses both above and below the mean were associated 
with a decreased risk of Alzheimer’s.  The protective effect was seen regardless of the 
length of time statins were used.  Data was collected from those patients over age 65 
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years, with similar results of AD and HRs (HR statin 0.61; 95% CI 0.38 to 0.98) (HR non 
statin 1.14; 95% CI 0.49 to 2.68).5 
The use of statin, but not non-statin cholesterol medication, was found to be 
associated with a lower risk of AD compared with the patients who did not take any types 
of cholesterol medication.  No difference was observed between lipophilic and 
hydrophilic medications.5  
Arvanitakis et al,4 evaluated the usage of statin therapy in relation to Alzheimer’s 
disease. This study included 929 older Catholic clergy members (68.7% women, mean 
age 74.9, mean MMSE 28.5) who were all free of dementia at baseline.  All participants 
agreed to annual structured clinical evaluations consisting of 19 neuropsychological tests 
and also consented to brain autopsy at time of death. 314 patients died, and 294 had a 
brain biopsy performed.4  
Cognition was assessed at baseline and at each follow up appointment and data 
reviewed by a neurophysiologist.  There were a total of 19 tests were used to assess 
global cognition on five separate cognitive domains: episodic memory, somatic memory, 
working memory, and visuospatial ability.  The MMSE was used. Medications taken by 
participants, including statins, were recorded. Statins were evaluated based on their 
lipophilic properties in relation to possible effects on BBB.  The time period during 
which statins were used by the participant was also reviewed.  More than 900 older 
patients without baseline dementia for up to 12 years with annual follow-up and did not 
find any relation of AD with statins, no changes in global cognition on five separate 
cognitive domains.4 
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After death, a blinded neurologist reviewed all clinical data.  Brain autopsies were 
performed and cut into 1 cm samples and examined for AD pathology using a silver stain 
to visualize any pathologic signs of AD.  The number of diffuse plaques, neuritic plaques 
(NPs), and neurofibrillary tangles (NFT) in each region was counted. A neuropathologic 
diagnosis of definite AD, probable, possible, or no AD was made. Amyloid-beta was 
measured using a microscope. To quantify the amount of tangles present, the protein Tau 
was labeled with AT8, and tangles were quantified by serology using a microscope.4 
The relation of statin usage to neurofibrillary tangles was examined.  It was found 
that of the 929 patients, 119 used statins (12.8%) at baseline, and 810 did not (87.2%).  
Of the statin users, 67 were taking more lipophilic statins (simvastatin and lovastatin).  
During the 12 year follow up period, 191 patients developed AD, 16 of these patients 
used statins at baseline (8.4%).   Using a Cox proportional hazards model, it was shown 
that baseline statin usage was not associated with a risk of AD compared to the non-statin 
users (HR=0.91; 95% CI 0.54, 1.52). The presence of ApoE4 did not change this finding 
and there was no interaction of statins seen with ApoE4.4  The relationship between 
lipophilic versus hydrophilic statins were examined (HR=1.05, 95% CI 0.57 to 1.95, and 
HR=0.71; 95% CI 0.29 to 1.74 respectively). There was no relationship found between 
the cumulative statin variable to incident AD (HR=0.93, 95% CI 0.56 to 1.55).  The 
relation of cognition of statin was examined and was found that statins were not 
associated with level (p>0.09 in all tests) or change (p>0.20) in global cognition or 
cognitive domains.  In patients who developed dementia, there was no relation of statins 
to change in global cognition (p=0.32).4 
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The mean age of death was 85.4 years (SD=6.8). The mean MMSE was 23.5 at 
the last clinical evaluation (with the mean time to death of 6.5 months).  1/3 had clinical 
dementia before death. Nearly all 262 subjects who underwent brain biopsy had some 
pathology of AD with a mean global AD score of 0.59 (range 0 to 1.50) in statin users 
and 0.70 (range 0 to 1.59) in those who did not use statins.  Of the 199 patients who had 
amyloid data present on biopsy, 16.6% were statin users,  statin users had less 
immunoreactivity compared to nonusers (0.92 vs. 1.97 units, p<0.01).  Of the patients, 
231 were found to have NFT evidence, with a mean age of 85.5 years. There was no 
difference between statin and non-statin users.  Results showed that 81 of the 262 patients 
had cerebral infarctions, which were present in 23.4% of statin users and 32.6% of 
nonusers (p=0.22).4 
All the models were adjusted for sex, education, and age at death.  It was found in 
a linear regression analysis that statins were not associated with the global AD score.  
Compared to non-statin users, higher or lower lipophilic properties was not associated 
with global AD pathology (p=0.28 for more lipophilic, p=0.76 for less lipophilic).  It was 
however found that higher lipophilic statin users were less likely to have amyloid buildup 
in the brains (p=0.03). There was no conection found between statins and infarctions 
(p=0.19).  More lipophilic statins were associated with lower likelihood of amyloid.  The 
relationship between statins and cerebral infarction was examined, and no relationship 
was found (OR=0.9, 95% CI: 0.4, 1.8).4 
Li et al,1 who started their study in 1994, also performed brain biopsies to 
evaluate the effect of statins on cognitive decline.  Typically AD related neuropathologic 
outcomes were monitored: including neurofibrillary tangles and neuritic plaques (NPs).  
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Statins were not widely used before the mid 1990s so older subjects were not treated with 
statins in their early older ages. Brain biopsies were performed on 110 subjects, from 65 
to 79 years old, who were cognitively normal at baseline.   Comparisons were made 
between statin users who took more than 4 months of statins and those who did not.1 
Each subject had a baseline neurocogntive examination and was followed twice 
per year for cognitive decline on the Cognitive Abilities Screening Instrument scale 
(CASI). Decline was detected by a score of less than 86.  Those who showed decline had 
an evaluation with a neuropsychological test battery and a physical and neurological 
examination by a neurologist or a geriatrician.  Laboratory values and brain CT or MRI 
scans were obtained as needed.  Total cholesterol and HDL values were measured 
although patients were generally not always fasting.   By 2006, 24% of the eligible 
sample had died, with the mortality rate being lower in the statin users than non-users (19 
vs. 26%, p<0.01).  Exposure to medications was determined from the GHC pharmacy 
database. All assessments were performed blind to clinical diagnosis and risk factors.  All 
brains were evaluated for gross lesions, atherosclerosis, cystic infarcts, ventricle 
enlargement, NPs, NFTs, and microvascular lesions.1 
Of the 110 subjects underwent brain biopsy, 36 (33%) had received greater than 
three prescriptions for statins.  Statin users were more likely male, and had a higher 
prevalence of cardiovascular disease or diabetes mellitus at enrollment and had higher 
total cholesterol levels.  Statin users were found to have slightly lower CASI scores at 
enrollment; however the incidence of dementia did not differ between the 2 groups.1  
Subjects received their first statin prescription at an average age or 76 (range 64 to 87) 
and the average number of prescriptions filled was 30 (range to 90).  Most participants 
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received simvastatin or lovastatin.   There was found to be no association between statin 
usage and dementia based on the CASI scores.1 
Brain autopsies showed statin users had a lower amount of both NFTs and NPs 
compared with non-users.  After controlling for age at death, CASI score, gender, brain 
weight, presence of MVL, it was found that statin users had a significantly decreased risk 
for typical AD neuropathology findings. Findings were consistent with statin usage 
associated with a decreased NFT burden on autopsy.  Alzheimer’s typical 
neuropathology, using the Braak and CERAD scores, were significantly less common in 
statin users than in non-users.1  
Cramer et al,11  examined the efficacy of statins in prevention of dementia over a 
five year period of time.  The population based cohort comprised of 1674 Mexican 
American patients over the age of 60 who were dementia free at baseline.  Cognitive and 
clinical evaluations were performed every 12 to 15 months.  Cox proportional hazard 
models were used to evaluate the association between statins and dementia.  Over a five 
year period of time, 130 participants developed dementia.   Statin dose, duration, 
frequency, and source were monitored at each patients home by inspection of all 
prescribed medications.  A semiannual phone call to and annual direct examination were 
made to each participant.  Covariates included DM, CVA, education, nativity, smoking 
status, insurance, and ApoE genotype.  Cognitive testing and evaluations were performed 
yearly. Dementia was diagnosed based on DSM-IV and NINCDS-ADRDA.  MMSE, 
Spanish and English verbal learning tests, and Informant Questionnaire on Cognitive 
Decline in the Elderly (IQCODE) were used to evaluate cognitive decline. A case review 
team included a geriatrician, neurologist, and a neuropsychologist who arbitrated all 
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potential dementia cases.  Diagnoses were based on the patient’s mental tests and 
findings form neurologic examination, Cases with dementia  were referred for an MRI 
and certain laboratory tests.11 
Of the 1674 patients free of dementia at the beginning of the study, 452 (27%) 
took statins at some point during the study.  Patients who took other cholesterol 
medications that were not in the statin class were not included in this category. Of the 
patients that took statins, 263 (58%) used them for longer than 2 years during the study.  
Participants in the statin class were found to be slightly younger, have increased 
education, more likely to have been born in the United States, and more likely to have 
medical insurance, as well as a higher percentage of patients with diabetes and higher 
baseline MMSE exam scores.5,9 A total of 130 participants developed dementia over the 
five year follow up.  Of those diagnosed with dementia: 48% had possible/probable AD, 
23% undetermined etiology, 13% ischemic vascular dementia, 13% had mixed AD or 
vascular dementia, and 3% had other types.11  
Cox proportional hazard models were used to examine the relationship between 
dementia and the use of statins. Baseline diabetes, stroke, education, smoking status, 
ApoE4 allele, and MMSE were all associated with dementia in unadjusted models.  Two 
adjusted models, diabetes and stroke were associated with statin use and included in the 
Model 1, and all significant covariates were included in Model 2.  There were no 
significant interactions between statin use and any covariates.5 In the adjusted analysis, 
statin use was associated with a 43% lower rate of dementia (HR 0.577, 95% CI 0.376, 
0.886).  In Model 1, statin use was associated with a 48% lower rate of dementia (HR 
0.518, 95% CI 0.336, 0.797). In Model 2 with all covariates included, there was a 44% 
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lower rate of dementia in statin users (HR 0.564, 95% CI 0.365, 0.872).   Baseline 
MMSE did not predict statin use, and there was found to be no interaction between the 2 
variables.  Statin use was found to be associated with a significant decrease in the 
incidence of dementia.11 
Bernick et al,13 examined the association of statin drug use on cognitive and MRI 
changes in older adults.  They performed a longitudinal study of participants over age 65, 
and were grouped into 3 categories according to whether they took statins continuously, 
intermittently, or not at all.   Patients who had a history of TIA or stroke or 3MS scores 
less than 80 were excluded.  Participants were monitored over an average of seven years 
based on their 3MS scores, along with changes in white matter and measures of atrophy 
on MRI.13 
A total of 5888 participants were eligible for the study.  It was a community based 
prospective epidemiologic study in adults over age 65. Patients underwent yearly 
cognitive testing and some underwent cranial MRIs. Data was collected by a baseline 
clinical visit, semiannual updates that alternated between phone calls and clinic visits, 
standard questionnaires, physical examinations, and laboratory testing.  Participants were 
followed for ten years, cognitive function was assessed using the 3MS, which assesses 
cognition in greater detail than the MMSE and ranges from 0 to 100. Scores of less than 
80 have a high specificity for dementia.  Certain participants underwent cranial MRI 
scans at two time points, generally four to five years apart. Imaging was interpreted by a 
neuroradiologist with training in this protocol and without knowledge of the subject’s 
clinical information.  The white matter changes and ventricular and sulcal size of each 
patient was assessed.13 
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Patients were excluded from statistical analysis if they: had incomplete lipid data, 
a baseline 3MS<80, less than two years of cognitive testing, no baseline 3MS, missing 
information of statin usage, or an incidental stroke or TIA. The remaining participants 
were divided into 3 groups:  
1. Untreated group who had received none or less than 2 years of statin therapy.  
2. Intermittent group who received between 2-4 years of continuous treatment or 3-5 
years of noncontinuous statin treatment.  
3.  Continuous group who received greater than 4 years of continuous statin therapy.13 
Cognitive decline was measured as the rate of change in 3MS per year.  The rate 
was modeled in a linear regression as the response variable.  A multivariate regression 
was used to adjust for factors that might have contributed to the relationship between 
cognitive decline and statins, including age, sex, ApoE4, education, and cholesterol.  
Univariate ANOVA was used to test the effect between treatment categories.13 
A total of 3660 participants underwent MRI examinations. After cross sectioning 
those who had an MRI at years five and ten with statin data, there were 1823 participants 
with an average interval of 5.1 years between scans for analysis of change.  MRI analysis 
included white matter, ventricular, and sulcal grade which were treated as continuous 
variables. Linear regression was used to examine the association of statin usage with the 
difference between first and second MRI results, after adjusting for covariates (white 
matter grade, ventricular size, sulcal size).13 
The baseline 3MS scores and other characteristics were similar among all groups.  
The adjusted and unadjusted mean in cognitive decline were evaluated. The adjusted 
model uses the covariates that were associated with cognitive decline and displays the 
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rate of change per year in treatment categories.  The unadjusted difference in mean rate of 
3MS between the continuous statin group and the intermittent statin group was 0.48 (95% 
CI 0.06, p=0.024). After adjusting for age, sex, ApoE, race, cholesterol and education, the 
difference in 3MS was 0.40 points per year (95% CI -0.03, 0.87, p=0.069). The 
unadjusted differences in 3MS between continuous statin compared with the untreated 
group was 0.49 (95% CI 0.12, 0.85 p=0.009), which remained significant even after 
adjustments (0.49, 95%CI 0.04, 0.95’ p=0.026).10  In MRI results, there was no 
significant difference in white matter, ventricular, or sulcal changes between continuous 
statin groups and untreated groups.  However, there was a fourfold increase in silent 
infarcts in the untreated group compared to the statin group.13  
The use of statin drugs was found to be associated with a slight decrease in 
cognitive decline in elderly patients.  In serial MRIs taken five years apart, there was no 
measurable difference in changes in white matter or atrophy between treatment groups.10  
Li et al14 examined the association between statin therapy and the risk of AD in a 
prospective cohort study with incident dementia and documented statin exposure.  A total 
of 2356 cognitively intact participants greater than 65 years of age when the study was 
started in 1994 were recruited. Subjects were randomly selected from a HMO and were 
assessed for dementia twice per year.  A total of 312 participants were identified with 
incident dementia, and of these 168 had probable AD.  Participants were screened using 
the Cognitive Abilities Screening Instrument (CASI) and those who scored higher than 
86 out of 100, and without evidence of baseline dementia were allowed into the cohort.  
ApoE genotyping was completed.14 
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A total of 312 participants developed dementia or probable AD, 363 participants 
died, and 186 refused participation, leaving 1496 cognitively normal participants at the 
end of the study in 2002.  Prescription history was obtained through a pharmacy database 
including dosage and frequency of statin medications. Subjects were screened using the 
CASI assessment every two years, and those who scored less than 86 underwent 
dementia diagnostic evaluation including a physical and neurologic examination by a 
neurologist, geriatrician or internist, and a one hour battery of neuropsychological testing.  
Laboratory tests and brain CTs or MRIs were obtained as needed. Diagnoses were made 
using criteria from the DSM-IV and NINCDS-ADRDA. Those diagnosed with dementia 
underwent at least one annual follow up visit to verify dementia and to assess cognitive 
decline.14 
Age at study entrance was found to be inversely associated with risk of dementia 
with a hazard ratio of 0.88 (95% CI 0.84-0.94).  The corresponding HR for probable AD 
was 0.91 (95% CI 0.84-0.98).  These results show that a one year increase in age at entry 
was associated  with a 12% decrease in relative risk for dementia and 9% decrease in 
relative risk for AD.  Each year of education was also found to be inversely related to the 
risk of dementia (HR 0.95, 95% CI 0.92-0.99) and probable AD (HR 0.92, 95% CI 0.87-
0.97).  The presence of the Apo4 allele was also associated with increased risk of 
dementia (HR=2.24, 95% CI 1.75 to 2.85) and probable AD (HR=2.57, 95% CI 1.85 to 
3.56).  Sex, race, BMI, and other vascular co morbidities were not found to have a 
significant association with dementia or probable AD.14 
A total of 392 of the 2356 participants had used statin drugs; some also used 
another non-statin form of lipid lowering medications.   Simvastatin was the most 
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commonly used followed by pravastatin. Unadjusted HR for statin users were 1.33 for 
dementia and 0.90 for probable AD, with confidence intervals that included 1.0, the null 
value.  Models that included ApoE, age, and education gave essentially unchanged 
results. There was no dose-dependent relationship evident between statin use and 
dementia.14 
Zandi et al15 examined the association of statins with dementia on a total of 5092 
patients ages 65 and older.  Participants were assessed in 1995-1997, and again in 1998 to 
2000.  Direct visual inspection of medications, including statins, was conducted at each 
visit.  Screening for dementia was done with the modified Mini-Mental Status Exam 
(3MS).  Patients who scored less than 87 on the 3MS at wave 1, or less than 84 on wave 2 
were further evaluated with the Dementia Questionnaire.  Those whose results suggested 
cognitive impairment were examined by physical assessment, structured neurological 
examination, and a one hour battery of neuropsychological tests.  Results were reviewed 
by a geriatric psychiatrist and neuropsychologist and the diagnosis of dementia was 
determined by the DSM-III-R.  Patients were then examined by a geriatric psychiatrist or 
neurologist and referred for neuroimaging and laboratory studies.  A consensus panel of 
experts in neurology, geriatric psychiatry, neuropsychology, and cognitive neuroscience, 
reviewed all data and assigned final diagnoses to patients.15  
During the first wave, 4895 patients were assessed with the number of demented 
patients found to be 255, which included 200 AD diagnoses. 99.4% of participants 
provided medication information and 292 (6%) were taking statin drugs, most commonly 
lovastatin, fluvastatin, and pravastatin.  During the second wave, 1232 patients were lost 
to death, relocation, or refusal to participate. Among the 3308 remaining, 185 had 
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developed dementia, including 104 with AD.  The number of statin users had grown to 
481 (14.7%), most commonly simvastatin, atorvastatin, and fluvastatin.  More than half 
(298) were prescribed statins between the 2 waves.15  
There was found to be a significant inverse in the effect of statin use with 
dementia at wave 1. After adjusting for age and sex, the OR shifted towards the null but 
remained significant (OR 0.45, 95% CI 0.18-0.95). After adjusting for education, ApoE 
these results did not significantly change. In adjusted analysis the hazard ratios were 
above the null of 1.0 for both dementia (HR=1.19, 95% CI 0.53-2.34) and AD (HR=1.19, 
95% CI0.35-2.96). Further analysis was performed which showed some reduced risk of 
dementia with longer usage of statins but results were not significant (p>0.40).  These 
results did not show any significant association between the use of statins and dementia 
or AD.15 
DISCUSSION 
The results of statin therapy used for prevention of dementia in the elderly 
population is inconsistent and unconvincing.  While three studies found benefits with 
statin usage, four studies found no significant benefits.  MRI results did not show 
significant variation in statin users versus non-users.  Brain autopsy results were also 
inconsistent, however, one study reported a decrease in the incidence of amyloid plaques 
and the other reported a decreased incidence in NPs and NFTs, which may play a role in 
the progression of dementia. However, this decrease in pathological findings did not have 
a significant effect on patient’s cognitive functioning during the end of their lifetime. 
All studies took into account variables that could have altered results and adjusted 
for these in their calculations.  These variables included age, race, education, and ApoE 
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presence. All studies eliminated patients with baseline dementia. These studies were 
cohort studies so did not involve randomization 
Since neither hydrophilic nor lipophilic has been shown to affect AD more than 
the another,4 it is proposed that many other factors determine the drug’s distribution into 
other tissues in the body.  They may act through a mechanism in which brain penetration 
is irrelevant.  Statins also affect other tissues by ways of endothelial functioning, 
atherosclerosis and oxidative stress reactions.  There was not shown to be any affect of 
statins and the ApoE4 genotype.5 
In more than 250 brains that were biopsied in the study performed by Arvanitakis 
et al,4 there was no connection found between statins and AD. However, it was seen that 
patients taking statins are less likely to have amyloid plaques than those who were not.4  
These results could be better tested by brain autopsies in subjects who started taking 
statin drugs earlier in life to determine if a significant change was seen with cognitive 
testing.   Overall, the results shown in this study do not support a protective effect of 
statins on AD or cognitive decline.4  
Other studies have yielded findings that statins may influence metabolism of the 
amyloid-precursor protein, by activation of an alpha secreatase activity, and have other 
effects that may decrease amyloid beta production.  Statins have also been found to calm 
cerebral inflammatory pathways by preventing glial production of cytokines, decreasing 
oxidative stress, and increasing cerebral circulation, and decreasing cholesterol in plasma 
membranes.4 
The mechanisms by which statins function in the brain is still unclear.  Animal 
studies have shown that high levels of cholesterol in the brain could alter amyloid 
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precursor protein (APP) processing, which results in accumulation of Beta-amyloid and 
the formation of NPs, and that statins can reverse these changes.1  However, trials in 
humans have failed to demonstrate a consistent effect of statins in altering CSF APP 
processing or beta-amyloid levels, or in slowing the progression of AD. Animal studies 
have also shows that statins may inhibit Tau phosphorylation from either inhibition of a 
possible amyloid cascade or via anti-inflammatory effects.14 
Bernick et al13 found that it was possible to slightly decrease cognitive decline 
with statin usage.  Previous multiyear treatment trial with pravastatin and simvastatin 
failed to show benefits in cognitive decline.  There have been multiple proposed 
mechanisms on how statins effect cognition: some are able to cross the blood brain 
barrier and may play a role in brain cholesterol modulation, which may play a role in 
neurotransmission and synaptic plasticity. Statins may also decrease oxidative stress and 
inflammation, increase endothelial nitric oxide synthase, and improve endothelial 
function and blood flow.  Subclinical vascular disease may also play a role in cognition 
which can be improved with statin therapy.13 
Hypercholesterolemia is known to be associated with vascular disorders, and is 
thought to play a role in the increased risk of dementia.15  High cholesterol may also 
influence dementia pathogenesis. Experiments in vivo and in vitro have shown that 
cholesterol accelerates the production of Alzheimer amyloid by shifting amyloid 
precursor protein (APP) metabolism from alpha to beta cleavage products. Statins might 
inhibit this process by lowering the amount of cholesterol available. They may also 
prevent atherothrombotic events via the action of smooth-muscle function, macrophages, 
or platelets, and may play a role in reduction of inflammatory responses that are thought 
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to work in Alzheimer’s pathogenesis by inhibiting nitric oxide synthase.15  Amyloid was 
found to be decreased after the use of statins in one study after brain biopsy.  More 
research is needed to determine the effects of statins on long term brain anatomy.  There 
was no proven benefit to the efficacy of MRI on the diagnosis of dementia.15  
Limitations of Study 
These studies were all cohort studies, no studies randomly assigned treatments to 
patient.  Patient statin usage was recorded based on the honor system.  Patients were 
prescribed medications, however, whether patients flowed through and took their 
medication is another question.   This is a large flaw that can affect the results of any 
study if the statin user group was not compliant with their medication. In forming groups 
for the studies, any statin usage was usually grouped in the same group regardless of 
whether they took statins for as little as six months or as long as ten years.  Baseline 
medications patients were taking prescribed by their individual providers were not altered 
or changed during the course of the studies.  Other factors that may affect the initiation of 
statins in elderly is that physicians may be less likely to start a new long term medication 
on demented patients, since they have a reduced ability to be compliant with their 
medications and are at greater risk of treatment related complications due to 
polypharmacy issues that may already be in effect.  Different studies used different 
measures and scales to examine the rate of cognitive decline so it is difficult to compare 
one study with the next.  It is also difficult to compare one study with the next when 
different grading scales and limitations are used in each study. With a more consistent, 
monitored study, the effect of statins in the treatment of dementia could better be 
monitored.  
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CONCLUSION 
Any treatment option that is available to prevent or reduce dementia is an 
important option for the patient as well as the health care provider.  Based on the results 
above, the evidence that statins decrease the incidence of dementia is unconvincing.  
However, none have shown to be harmful to the patient and the use of statins has great 
positive effects on other processes in the body such as cardiovascular events and the use 
of statins should be a consideration in all patients’ healthcare.  More trials need to be 
done for longer periods of time and looking into the outcomes of statins and dementia 
when participants begin statins at middle ages, long before signs of dementia may begin 
to manifest themselves.  
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TABLES 
TABLE 1: Summary Matrix of Reviewed Literature 
 
Study/Design 
 
Population 
Exams Done 
Intervention Comparison Outcome(s) Validity 
x/ 5 
Li et al.1  
(2007) 
Population based 
study 
110 
>65yrs 
Brain biopsies 
Statin vs. no 
statins. 
Neurofibrillary 
tangle burden and 
neuritic plaques on 
brain autopsy  
Decreased association between 
statin use and NFTs and NPs 
on autopsy. Dementia did not 
differ between groups.   
OR=0.44, 95% CI 0.20-0.95 
5/5 
Haag, et al.5 
(2009) 
Prospective 
population based 
6992  
>55yrs 
MMSE 
GMS 
Statins vs No-
statins. 
Lipophilic statins 
vs. hydrophilic 
statins 
Prevalence of AD Statin use was assoc w/ a 
decreased risk of AD (HR 0.57, 
95% CI 0.37 to 0.90) HRs were 
equal for both lipophilic and 
hydrophilic statins (HR 0.54 
both, 95% CI: 0.32-0.89, and 
0.26-1.11) respectively 
4/5 
Cramer et al.11 
(2008) 
Population based 
cohort 
1789  
>60yrs 
3MSE 
Statin usage vs. 
no-statin usage 
Prevalence of AD 
based on 3MSE.  
Statins were associated with 
signif decrease in dementia. 
HR 0.577 (95% CI 0.376-
0.886) p=0.012 
3/5 
Arvanitakis et al.4 
(2008) 
Longitudinal  
clinical 
pathologic study 
929  
>65yrs 
Brain Autopsy 
Statin  vs. no-
statin  
Prevalence of AD 
and Brain 
composition in 
statin users vs. non-
users.  
Statin use at baseline (12.8%) 
was not assoc w/ incident AD, 
change in global cognition, or 
change in cognitive domain.  
Statin use prior to death was 
not related to global AD 
pathology. Those taking statins 
were less likely to have 
amyloid (p=0.02).. Statins were 
not related to NFTs or 
infarctions. 
HR=0.91, 95% CI 0.54-1.52. 
p=0.32 
5/5 
Bernick et al.13 
(2005) 
Community based 
prospective 
Epidemiologic 
cohort  
3334 pts. 
>65yrs 
BrainMRI 
3MSE 
Continuous statin 
usage vs. 
Intermittent statin 
use vs. No statin 
usage 
Prevalence of AD.  
Changes in Cranial 
MRI between statin 
users and non-statin 
users 
Rate of decline of cognition for 
statin users was 0.48/yr less 
than untreated group. 
MRI results show no sig 
changes in white matter grade 
or atrophy in statin users. 
95%CI 0.06-0.89, p=0.024 
4/5 
Li et al.14 
(2004) 
Community based 
prospective 
cohort 
2356  
>65yrs 
Neuro 
assessment 
Statin vs. no 
statin in dementia 
Prevelence of 
dementia  
Statins not found to prevent 
dementia 
HR 1.19, 95% CI 0.82-1.75 
4/5 
Zandi et al.15 
(2005) 
Cross sectional 
prospective study 
4895  
>65yrs 
Statin tx vs. no 
statin  
Prevalence of 
dementia and AD 
Statins was inversely assoc w/ 
dementia prevalence, however 
3 years later when pts 
reexamined, statin use was not 
found to predict incidence of 
dementia or AD. 
OR 1.19, 95%CI 0.53-2.34 
3/5 
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